Sepsis is a leading healthcare problem, accounting for the vast majority of fatal events in critically ill patients. Beyond early diagnosis and appropriate treatment, this condition requires a multifaceted approach for monitoring the severity, the potential organ failure as well as the risk of death. Monitoring of the efficacy of treatment is also a major issue in the emergency department (ED). The assessment of critically ill conditions and the prognosis of patients with sepsis is currently based on some scoring systems, which are, however, inefficient to provide definite clues about organ failure and prognosis in general. The discretionary and appropriate use of some selected biomarkers such as procalcitonin, inducible protein 10
(IP10), Group IV phospholipase A2 type II (PLA2 II),
neutrophil gelatinase-associated lipocalin (NGAL),
natriuretic peptides, mature adrenomedullin (ADM),
mid-regional pro-adrenomedullin (MR-proADM), copeptin,
thrombopoietin, Mer receptor and even red blood
cell distribution width (RDW) represent thereby an
appealing perspective in the diagnosis and management
of patients with sepsis. Nevertheless, at the moment,
it is not still clear if it is better to use a multimarkers
approach or if a single, most appropriate, biomarker
exists. This collective opinion paper is aimed at providing
an overview about the potential clinical usefulness of some innovative biomarkers of sepsis in its diagnosis and prognosis, but also in the treatment management of the disease. This manuscript represents a synopsis of the lectures of Third Italian GREAT Network Congress, that was hold in Rome, 15 – 19 October 2012.
